Article Text

Download PDFPDF
Randomised controlled trial
Thromboprophylaxis in heart failure patients with sinus rhythm: aspirin and warfarin lead to similar cardiovascular outcomes
  1. Klaus K A Witte,
  2. Haqeel A Jamil
  1. Division of Cardiovascular and Diabetes Research, University of Leeds, Leeds, West Yorkshire, UK
  1. Correspondence to: Klaus K A Witte Division of Cardiovascular and Diabetes Research, LIGHT laboratories, University of Leeds, Leeds, West Yorkshire LS2 9JT, UK; k.k.witte{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on: OpenUrlCrossRefPubMedWeb of Science


Chronic heart failure (CHF) is common, affecting 1–2% of the population and 10% of people >70 years. Patients with CHF have an increased risk of thromboembolism. Those with atrial fibrillation (AF) should receive warfarin but whether CHF patients with sinus rhythm (SR), whose risk is 1.5–3.5%,1 should receive thromboprophylaxis is unclear.

Previous studies, Warfarin/Aspirin Study in Heart failure (warfarin, aspirin 300 mg daily, placebo),2 Heart failurE Long-term Antithrombotic Study (aspirin 325 mg daily or warfarin for patients with ischaemic heart disease (IHD) or warfarin or placebo in the non-ischaemics)3 and Warfarin and Antiplatelet Therapy in Chronic Heart failure (WATCH: warfarin, clopidogrel 75 mg daily, …

View Full Text


  • Competing interests None.